Scott M. Steward-Tharp

Scott M. Steward-Tharp

Auto-generated profile, based on publicly available information

Scott M. Steward-Tharp

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, GA, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
KGKamran Ghoreschi
Kamran Ghoreschi
MJMichael I Jesson
Michael I Jesson
XLXiong Li
Xiong Li
JLJamie L. Lee
Jamie L. Lee
SGSarbani Ghosh
Sarbani Ghosh
JOJohn J. O’shea
John J. O’shea
Inhibitors of the JAK family of nonreceptor tyrosine kinases have demonstrated clinical efficacy in rheumatoid arthritis and other inflammatory disorders; however, the precise mechanisms by which JAK inhibition improves inflammatory immune responses remain unclear. In this study, we examined the mode of action of tofacitinib (CP-690,550) on JAK/STAT signaling pathways involved in adaptive and innate immune responses. To determine the extent of inhibition of specific JAK/STAT-dependent pathways, we analyzed cytokine stimulation of mouse and human T cells in vitro. We also investigated the consequences of CP-690,550 treatment on Th cell differentiation of naive murine CD4+ T cells. CP-690,550 inhibited IL-4–dependent Th2 cell differentiation and interestingly also interfered with Th17 cell differentiation. Expression of IL-23 receptor and the Th17 cytokines IL-17A, IL-17F, and IL-22 were blocked when naive Th cells were stimulated with IL-6 and IL-23. In contrast, IL-17A production was enhanced when Th17 cells were differentiated in the presence of TGF-β. Moreover, CP-690,550 also prevented the activation of STAT1, induction of T-bet, and subsequent generation of Th1 cells. In a model of established arthritis, CP-690,550 rapidly improved disease by inhibiting the production of inflammatory mediators and suppressing STAT1-dependent genes in joint tissue. Furthermore, efficacy in this disease model correlated with the inhibition of both JAK1 and JAK3 signaling pathways. CP-690,550 also modulated innate responses to LPS in vivo through a mechanism likely involving the inhibition of STAT1 signaling. Thus, CP-690,550 may improve autoimmune diseases and prevent transplant rejection by suppressing the differentiation of pathogenic Th1 and Th17 cells as well as innate immune cell signaling.

30 January 2011 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
XYXiang-Ping Yang
Xiang-Ping Yang
KGKamran Ghoreschi
Kamran Ghoreschi
SSScott M Steward-Tharp
Scott M Steward-Tharp
JRJaime Rodriguez-Canales
Jaime Rodriguez-Canales
JZJinfang Zhu
Jinfang Zhu
ALArian Laurence
Arian Laurence

8 May 2014 in Blood
Verified
Journal Article
Open access
PDF file
SSScott M. Steward-Tharp
Scott M. Steward-Tharp
ALArian Laurence
Arian Laurence
YKYuka Kanno
Yuka Kanno
AKAlex Kotlyar
Alex Kotlyar
AVAlejandro V. Villarino
Alejandro V. Villarino
JOJohn J. O'SHea
John J. O'SHea
Mutations of STAT3 underlie the autosomal dominant form of hyperimmunoglobulin E syndrome (HIES). STAT3 has critical roles in immune cells and thus, hematopoietic stem cell transplantation (HSCT), might be a reasonable therapeutic strategy in this disease. However, STAT3 also has critical functions in nonhematopoietic cells and dissecting the protean roles of STAT3 is limited by the lethality associated with germline deletion of Stat3. Thus, predicting the efficacy of HSCT for HIES is difficult. To begin to dissect the importance of STAT3 in hematopoietic and nonhematopoietic cells as it relates to HIES, we generated a mouse model of this disease. We found that these transgenic mice recapitulate multiple aspects of HIES, including elevated serum IgE and failure to generate Th17 cells. We found that these mice were susceptible to bacterial infection that was partially corrected by HSCT using wild-type bone marrow, emphasizing the role played by the epithelium in the pathophysiology of HIES. Key Points Mice that express a mutation in STAT3 phenocopy patients with HIES. Bone marrow transplantation does not fully correct the susceptibility of these animals to bacterial infection.

14 January 2006 in Biochemistry
Verified
Journal Article
Closed access
LWLin Wang
Lin Wang
STScott Tharp
Scott Tharp
TSTzvia Selzer
Tzvia Selzer
SBStephen J. Benkovic
Stephen J. Benkovic
AKAmnon Kohen
Amnon Kohen

1 April 2009 in Microbes and Infection
Verified
Journal Article
Closed access
JOJohn J. O'SHea
John J. O'SHea
SSScott M. Steward-Tharp
Scott M. Steward-Tharp
ALArian Laurence
Arian Laurence
WWWendy T. Watford
Wendy T. Watford
LWLai Wei
Lai Wei
SFSamuel Fan
Samuel Fan

12 January 2010 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SSScott M. Steward‐Tharp
Scott M. Steward‐Tharp
YSYun‐Jeong Song
Yun‐Jeong Song
RSRichard M. Siegel
Richard M. Siegel
JOJohn J. O'Shea
John J. O'Shea